MedTrace Logo

Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy

NCT00307164 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 167

Last updated 2021-11-04

Study results available
· View outcomes & findings →

Summary

Lipoatrophy, the loss of body fat from particular areas of the body, is a common side effect of antiretroviral therapy (ART). The purpose of this study was to determine the effectiveness of uridine supplementation in treating HIV infected individuals on stable ART with lipoatrophy.

Conditions

  • HIV Infections
  • Lipoatrophy

Interventions

DRUG

NucleomaxX

36 g sachet taken orally three times daily

DRUG

NucleomaxX placebo

36 g placebo sachet taken orally three times daily

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Grace A. McComsey, MD · Division of Infectious Diseases, Case Western Reserve University

  • Judith A. Aberg, MD · New York University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00307164 on ClinicalTrials.gov